Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.
In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.
TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
Vascarta and CUNY report positive preclinical results in glioblastoma treatment
Johnson & Johnson reports durable two-year remission data for TREMFYA in Crohn's disease
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps